Clinical phenotype and pathophysiological mechanisms underlying qualitative low VWF
- PMID: 40279514
- PMCID: PMC12333228
- DOI: 10.1182/blood.2024028035
Clinical phenotype and pathophysiological mechanisms underlying qualitative low VWF
Abstract
Previous reports have highlighted that some patients with low von Willebrand factor (VWF) with significant bleeding were diagnosed based on an isolated but persistent reduction in plasma VWF activity levels in the 30 to 50 IU/dL range. These patients had plasma VWF antigen (VWF:Ag) levels >50 IU/dL and thus had qualitative low VWF (low VWF-QL) rather than quantitative low VWF. Although the clinical importance of functional VWF defects in type 2 von Willebrand disease (VWD) is well recognized, the translational implications of mild functional defects in patients with low VWF-QL have not been defined. To address this clinically important question, we combined low VWF data sets from the low VWF in Ireland cohort and the low VWF in Erasmus MC studies. Overall, we observed that low VWF-QL was common and accounted for ∼50% of our combined low VWF cohort. Importantly, our findings demonstrated that many of these patients with mild isolated functional VWF defects in the 30 to 50 IU/dL range had significant bleeding phenotypes, although their plasma VWF:Ag levels were within the normal range. In addition, we further showed that low VWF-QL is a distinct clinicopathological entity compared to type 2 VWD. Finally, our studies highlighted that low VWF-QL is predominantly caused by abnormalities in VWF biosynthesis within endothelial cells that are occurring largely independent of identifiable pathological VWF sequence variants. Cumulatively, these novel observations have important clinical implications for the diagnosis and management of patients with mild functional VWF defects.
© 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Conflict of interest statement
Conflict-of-interest disclosure: F.W.G.L. reports receiving unrestricted grants/research funding from CSL Behring, UniQure, Sobi, and Takeda; receiving consultancy fees from BioMarin, CSL Behring, Takeda, and UniQure (all fees to the institution); and serving as data safety and monitoring board member for a study sponsored by Roche. J.S.O. reports serving on the speaker’s bureau for Baxter, Bayer, Novo Nordisk, Sobi, Boehringer Ingelheim, Leo Pharma, Takeda, and Octapharma; serving on the advisory boards of Baxter, Sobi, Bayer, Octapharma, CSL Behring, Daiichi Sankyo, Boehringer Ingelheim, Takeda, and Pfizer; and receiving research grant funding awards from 3M, Baxter, Bayer, Pfizer, Shire, Takeda, and Novo Nordisk. D.D. reports receiving honoraria from Takeda and receiving educational support sponsorship from Novo Nordisk and Amgen. M.L. reports receiving consultancy fees from Sobi, Band Therapeutics, and CSL Behring; receiving honoraria from CSL Behring and Pfizer; and receiving indirect funding for the development of educational content from Takeda. J.G.v.d.B. reports receiving research funding from Novo Nordisk. N.M.O. reports serving on the advisory boards of Sobi, F. Hoffmann-La Roche Ltd, UniQure, and Freeline and serving on the speaker’s bureau for Novo Nordisk. F.C.J.I.H.-M. reports receiving an unrestricted grant from Octapharma. S.E.M.S. reports receiving research funding from Bayer. R.I.B. reports that the institution received research support/clinical trial funding from Bayer, Takeda, Pfizer, Daiichi Sankyo, CSL Behring, Roche, Amgen, AstraZeneca, AbbVie, Sanofi, Acerta Pharma, Janssen-Cileg, Bristol Myers Squibb, Boehringer Ingelheim, Werfen, and Technoclone unrelated to the current study. M.B. reports receiving consultancy fees from Sobi. K.M. reports receiving speaker fees from Alexion, Bayer, and CSL Behring; participating in trial steering committees for Bayer and AstraZeneca; receiving consulting fees from UniQure and Therini Bio; and participating in data monitoring and end point adjudication committee for Octapharma (all fees paid to the institution). J.E. reports receiving unrestricted research funding from CSL Behring. P.J. reports receiving research funding from Bayer and receiving consultancy fees from Band/Guardian Therapeutics, Star/Vega Therapeutics, and Roche. K.F. reports receiving unrestricted grants/research funding from CSL Behring, Sobi, and Takeda for research unrelated to the current study and receiving consultancy fees from Sobi, Sanofi, Takeda, Novo Nordisk, and Roche (all fees to the institution). K.P.M.v.G. reports receiving an unrestricted research grant from Octapharma. The remaining authors declare no competing financial interests.
Comment in
-
Type 1 von Willebrand disease: does it need a sibling?Blood. 2025 Jul 17;146(3):270-271. doi: 10.1182/blood.2025029448. Blood. 2025. PMID: 40674123 No abstract available.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous